GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (OSTO:GENO) » Definitions » EV-to-FCF

Genovis AB (OSTO:GENO) EV-to-FCF : 57.61 (As of Dec. 13, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Genovis AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genovis AB's Enterprise Value is kr1,635.3 Mil. Genovis AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was kr28.4 Mil. Therefore, Genovis AB's EV-to-FCF for today is 57.61.

The historical rank and industry rank for Genovis AB's EV-to-FCF or its related term are showing as below:

OSTO:GENO' s EV-to-FCF Range Over the Past 10 Years
Min: -4728.45   Med: 45.96   Max: 774.84
Current: 55.99

During the past 13 years, the highest EV-to-FCF of Genovis AB was 774.84. The lowest was -4728.45. And the median was 45.96.

OSTO:GENO's EV-to-FCF is ranked worse than
81.14% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs OSTO:GENO: 55.99

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), Genovis AB's stock price is kr25.65. Genovis AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.420. Therefore, Genovis AB's PE Ratio (TTM) for today is 61.07.


Genovis AB EV-to-FCF Historical Data

The historical data trend for Genovis AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB EV-to-FCF Chart

Genovis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.59 -121.41 113.46 -619.11 61.16

Genovis AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.70 61.16 51.91 46.32 57.25

Competitive Comparison of Genovis AB's EV-to-FCF

For the Biotechnology subindustry, Genovis AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovis AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genovis AB's EV-to-FCF falls into.



Genovis AB EV-to-FCF Calculation

Genovis AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1635.256/28.386
=57.61

Genovis AB's current Enterprise Value is kr1,635.3 Mil.
Genovis AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr28.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genovis AB  (OSTO:GENO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Genovis AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.65/0.420
=61.07

Genovis AB's share price for today is kr25.65.
Genovis AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.420.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genovis AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genovis AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genovis AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Box 790, Lund, SWE, SE-220 07
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines